Dr. Hind Elsaid, MD (she/her) is a Nephrologist, Internist in Binghamton, NY with over 17 years of experience. What is your opinion of Dr. Hind Elsaid, MD? Rate this provider below so other people can make informed decision.
Gender
Female
Experience
Over 17 Years of Experience
Languages Spoken
English
Accepted Insurances
Medicare
Payments Received
Many providers receive payments from medical companies such as pharmaceutical companies and medical device companies. These payments can range from small amounts for meals to large consulting fees. We provide this information in order to make healthcare system more transparent. Between 2014 and 2020 Dr. Hind Elsaid, MD has received over $1,464 which includes payments from the following companies:
$316.40 from Relypsa, Inc.
$158.22 from Otsuka America Pharmaceutical, Inc.
$124.25 from Veloxis Pharmaceuticals, Inc.
$120.64 from AstraZeneca Pharmaceuticals LP
$102.38 from Sunovion Pharmaceuticals Inc.
$94.76 from Fresenius USA Marketing, Inc.
$81.56 from Daiichi Sankyo Inc.
$76.37 from Allergan Inc.
$69.36 from Shire North American Group Inc
$49.11 from AKEBIA THERAPEUTICS INC
$46.95 from Questcor Pharmaceuticals
$38.75 from Keryx Biopharmaceuticals, Inc.
$38.42 from Alexion Pharmaceuticals, Inc.
$28.48 from Janssen Pharmaceuticals, Inc
$21.39 from Otsuka Pharmaceutical Development & Commercialization, Inc.
$19.45 from Mallinckrodt Hospital Products Inc.
$18.58 from Takeda Pharmaceuticals U.S.A., Inc.
$18.28 from Pfizer Inc.
$15.60 from Merck Sharp & Dohme Corporation
$14.99 from NxStage Medical, Inc.
Payments received by Dr. Hind Elsaid, MD were from the following categories:
Do you have any questions about your diabetes condition or general questions about diabetes? You can now post those questions in DiabetesIQ Forum and have our diabetes experts answer your questions for FREE! Yes, there is absolutely no catch! - Registration only takes a few seconds and it's FREE. No credit card needed. You can ask any number of diabetes questions, all for FREE! Register today and join the conversation!